Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab

In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat cGVHD and other fibrotic diseases Shots: The companies collaborated to develop and commercialize Syndax’s axatilimab (anti-CSF-1R mAb) & will get a 50:50 US profit share …

Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab Read More »